I-Mab ex­pands man­u­fac­tur­ing for mul­ti­ple myelo­ma an­ti­body; Gran­ules is­sued 'mi­nor ob­ser­va­tion­s' af­ter in­spec­tion

Chi­na-based bio­phar­ma I-Mab has land­ed a part­ner­ship with Shang­hai’s Hangzhou Qiantang New Area to man­u­fac­ture drugs lo­cal­ly and speed up the com­pa­ny’s path to­ward com­mer­cial­iza­tion.

The deal will help it com­mer­cial­ize felzartam­ab, a mon­o­clon­al an­ti­body that tar­gets mul­ti­ple myelo­ma, in Chi­na. Hangzhou has start­ed op­er­at­ing on what it calls a Phase I site and start­ed con­struc­tion in De­cem­ber on an 80,000 square-me­ter spot for Phase II.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN